• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

hsa-mir-210 是肿瘤乏氧的标志物和头颈部癌症的预后因素。

hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer.

机构信息

Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

出版信息

Cancer. 2010 May 1;116(9):2148-58. doi: 10.1002/cncr.25009.

DOI:10.1002/cncr.25009
PMID:20187102
Abstract

BACKGROUND

Hypoxia is an important mechanism of treatment resistance in head and neck squamous cell carcinoma (HNSCC). MicroRNAs are short noncoding RNAs that regulate multiple mRNAs and are frequently dysregulated in cancer. The authors have investigated the role of 3 microRNAs, including the hypoxia-induced hsa-miR-210, as potential markers of hypoxia or prognosis.

METHODS

Three hypoxia-related microRNAs, hsa-miR-210, hsa-miR-21, and hsa-miR-10b, were measured in 46 samples from patients with HNSCC. Expression levels were correlated with clinicopathological variables and other markers of hypoxia: a published 99-gene hypoxia metagene, individual hypoxia-related genes such as TWIST1, and immunohistochemical expression of hypoxia-inducible factor 1 and its target gene carbonic anhydrase 9. We then performed survival analyses to investigate the prognostic significance of these microRNAs.

RESULTS

Only the level of hsa-miR-210 was significantly correlated with other markers of hypoxia, including the 99-gene hypoxia metagene (rho = 0.67, P < .001). We found no association between hsa-miR-210, hsa-miR-21, or hsa-miR-10b and clinicopathological variables such as tumor size, differentiation, and stage. However, high levels of hsa-miR-210 were associated with locoregional disease recurrence (P = .001) and short overall survival (P = .008). hsa-miR-21 and hsa-miR-10b had no prognostic significance.

CONCLUSIONS

Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis. This warrants further study as a classification marker of patients for therapies involving modulation of hypoxia.

摘要

背景

缺氧是头颈部鳞状细胞癌(HNSCC)治疗耐药的重要机制。miRNAs 是短的非编码 RNA,可调节多个 mRNA,并且在癌症中经常失调。作者研究了 3 种 microRNAs(包括缺氧诱导的 hsa-miR-210)作为潜在的缺氧或预后标志物的作用。

方法

在 46 例 HNSCC 患者的样本中测量了 3 种与缺氧相关的 microRNAs(hsa-miR-210、hsa-miR-21 和 hsa-miR-10b)。表达水平与临床病理变量和其他缺氧标志物相关:已发表的 99 基因缺氧荟萃基因、TWIST1 等个别缺氧相关基因以及缺氧诱导因子 1 及其靶基因碳酸酐酶 9 的免疫组织化学表达。然后,我们进行了生存分析,以研究这些 microRNAs 的预后意义。

结果

只有 hsa-miR-210 的水平与其他缺氧标志物显著相关,包括 99 基因缺氧荟萃基因(rho = 0.67,P <.001)。我们没有发现 hsa-miR-210、hsa-miR-21 或 hsa-miR-10b 与肿瘤大小、分化和分期等临床病理变量之间的关联。然而,高水平的 hsa-miR-210 与局部区域疾病复发(P =.001)和总生存时间短(P =.008)相关。hsa-miR-21 和 hsa-miR-10b 没有预后意义。

结论

hsa-miR-210 在头颈部癌症中的表达与评估缺氧的其他方法相关,并且与预后相关。这需要进一步研究作为治疗患者的分类标志物,包括缺氧调节疗法。

相似文献

1
hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer.hsa-mir-210 是肿瘤乏氧的标志物和头颈部癌症的预后因素。
Cancer. 2010 May 1;116(9):2148-58. doi: 10.1002/cncr.25009.
2
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer.人源微小RNA-210由缺氧诱导产生,是乳腺癌的一个独立预后因素。
Clin Cancer Res. 2008 Mar 1;14(5):1340-8. doi: 10.1158/1078-0432.CCR-07-1755.
3
Co-targeting of multiple microRNAs on factor-Inhibiting hypoxia-Inducible factor gene for the pathogenesis of head and neck carcinomas.多种微小RNA共同靶向抑制缺氧诱导因子基因在头颈部癌发病机制中的作用
Head Neck. 2016 Apr;38(4):522-8. doi: 10.1002/hed.23912. Epub 2015 Jun 16.
4
Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers.miR-29c、miR-200b和miR-375在头颈癌肿瘤组织及癌旁组织中的表达谱
Tumour Biol. 2016 Sep;37(9):12627-12633. doi: 10.1007/s13277-016-5147-2. Epub 2016 Jul 20.
5
Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.晚期头颈癌中骨桥蛋白的免疫组织化学检测:预后作用及其与氧电极测量、缺氧诱导因子-1α相关标志物和血红蛋白水平的相关性
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1481-7. doi: 10.1016/j.ijrobp.2006.07.1376. Epub 2006 Oct 23.
6
Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma.微小RNA let-7d和miR-205的低水平表达是头颈部鳞状细胞癌的预后标志物。
Am J Pathol. 2009 Mar;174(3):736-45. doi: 10.2353/ajpath.2009.080731. Epub 2009 Jan 29.
7
miR-21 increases the programmed cell death 4 gene-regulated cell proliferation in head and neck squamous carcinoma cell lines.微小RNA-21增加头颈部鳞状细胞癌细胞系中程序性细胞死亡4基因调控的细胞增殖。
Oncol Rep. 2014 Nov;32(5):2283-9. doi: 10.3892/or.2014.3456. Epub 2014 Sep 1.
8
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.前列腺癌中 microRNA 谱分析的诊断和预后意义。
Int J Cancer. 2010 Mar 1;126(5):1166-76. doi: 10.1002/ijc.24827.
9
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.缺氧标志物CA IX和GLUT 1以及细胞因子VEGF和IL 6在接受放疗+/-化疗的头颈部鳞状细胞癌中的预后价值。
BMC Cancer. 2005 Apr 25;5:42. doi: 10.1186/1471-2407-5-42.
10
The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.内源性缺氧相关标志物对头颈部鳞状细胞癌行加速放疗联合顺铂治疗的预后价值
Radiother Oncol. 2006 Jun;79(3):288-97. doi: 10.1016/j.radonc.2006.04.008. Epub 2006 May 26.

引用本文的文献

1
Strategies to Overcome Intrinsic and Acquired Resistance to Chemoradiotherapy in Head and Neck Cancer.克服头颈癌对放化疗的内在和获得性耐药的策略
Cells. 2024 Dec 27;14(1):18. doi: 10.3390/cells14010018.
2
miR-210 in ischaemic stroke: biomarker potential, challenges and future perspectives.miR-210 在缺血性脑卒中中的作用:生物标志物的潜力、挑战和未来展望。
Eur J Med Res. 2024 Aug 23;29(1):432. doi: 10.1186/s40001-024-02029-6.
3
Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma.
尿 microRNA-210-3p 作为一种新型的非侵入性生物标志物,用于检测胰腺癌,包括导管内乳头状黏液性肿瘤。
BMC Cancer. 2024 Jul 28;24(1):907. doi: 10.1186/s12885-024-12676-x.
4
Regulation of Cancer-Associated miRNAs Expression under Hypoxic Conditions.缺氧条件下癌症相关 miRNAs 表达的调控。
Anal Cell Pathol (Amst). 2024 May 10;2024:5523283. doi: 10.1155/2024/5523283. eCollection 2024.
5
Targeting hypoxia signaling pathways in angiogenesis.靶向血管生成中的缺氧信号通路。
Front Physiol. 2024 Apr 25;15:1408750. doi: 10.3389/fphys.2024.1408750. eCollection 2024.
6
Tumor hypoxia and role of hypoxia-inducible factor in oral cancer.肿瘤缺氧与口腔癌中缺氧诱导因子的作用。
World J Surg Oncol. 2024 Jan 11;22(1):18. doi: 10.1186/s12957-023-03284-3.
7
MiR-210-3p enhances intermittent hypoxia-induced tumor progression via inhibition of E2F3.miR-210-3p 通过抑制 E2F3 增强间歇性低氧诱导的肿瘤进展。
Sleep Breath. 2024 May;28(2):607-617. doi: 10.1007/s11325-023-02925-x. Epub 2023 Sep 29.
8
The Potential microRNA Prognostic Signature in HNSCCs: A Systematic Review.头颈部鳞状细胞癌中潜在的微小RNA预后标志物:一项系统评价
Noncoding RNA. 2023 Sep 14;9(5):54. doi: 10.3390/ncrna9050054.
9
Unraveling Therapeutic Opportunities and the Diagnostic Potential of microRNAs for Human Lung Cancer.揭示微小RNA在人类肺癌中的治疗机会和诊断潜力
Pharmaceutics. 2023 Jul 31;15(8):2061. doi: 10.3390/pharmaceutics15082061.
10
Peptide cargo administration: current state and applications.肽类药物的投药:现状与应用。
Appl Microbiol Biotechnol. 2023 May;107(10):3153-3181. doi: 10.1007/s00253-023-12512-5. Epub 2023 Apr 13.